RTP Mobile Logo

Andre T et al. Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. Gastrointestinal Cancers Symposium 2018;Abstract 553.

Arnold D et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28(8):1713-29. Abstract

Bardelli A et al. Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer. Proc ASCO 2018;Abstract 3506.

Bekaii-Saab TS et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) — An ACCRU Network study. Gastrointestinal Cancers Symposium 2018;Abstract 611.

Bendell J et al. Phase Ib/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). ESMO World Congress on Gastrointestinal Cancer 2017;Abstract LBA-003.

Corcoran RB et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 2018;8(4):428-43. Abstract

Diaz LA et al. Keynote-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC). Gastrointestinal Cancers Symposium 2018;Abstract TPS877.

Grothey A et al. Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL — A multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Proc ESMO 2018;Abstract LBA19.

Hamauchi S et al. Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer 2017;16(1):51-7. Abstract

Jones JC et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol 2017;35(23):2624-30. Abstract

Le DT et al. KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. Proc ASCO 2018;Abstract 3514.

Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509-20. Abstract

Lemery S et al. First FDA approval agnostic of cancer site — When a biomarker defines the indication. N Engl J Med 2017;377(15):1409-12. Abstract

Lenz H et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Proc ESMO 2018;Abstract LBA18_PR.

Lesniewski-Kmak K et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. Proc ESMO World Congress on Gastrointestinal Cancer 2018;Abstract O-022.

Overman MJ et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 2017;18(9):1182-91. Abstract

Salem ME et al. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer 2018;103:205-13. Abstract

Siena S et al. Final results of the HERACLES trial in HER2-amplified colorectal cancer. Proc AACR 2017;Abstract CT005.

Tabernero J et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). Proc ASCO 2017;Abstract 3002.

Van Cutsem E et al. BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. Proc ESMO World Congress on Gastrointestinal Cancer 2018;Abstract O-027.

Van Cutsem E et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: Results of the large, single-arm, open-label phase IIIb CONSIGN study. Oncologist 2018;[Epub ahead of print]. Abstract

Van Cutsem E et al; RECOURSE Study Group. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 2018;90:63-72. Abstract

Van Cutsem E, Dekervel J. Not all BRAF-mutant metastatic colorectal cancers are identical: Distinct clinical consequences of non-V600BRAF mutations. J Clin Oncol 2017(23):2598-9. Abstract

Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27(8):1386-422. Abstract

Xu J et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA study. J Clin Oncol 2018;36(4):350-58. Abstract